NCT04808310

Brief Summary

The aim of this study is to study whether the use of complex 3-dimensional assessment of the severity of a stenosis improves angina and in general cardiovascular outcomes in patients who have residual intermediate coronary artery stenosis following an acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). Goals of the study are:

  • To investigate whether decision-making based on quantitative flow reserve (QFR) is associated with a decrease in angina 3 months after an ACS
  • To investigate whether use of QFR is associated with an improved prognosis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P50-P75 for phase_4 coronary-artery-disease

Timeline
Completed

Started Oct 2020

Typical duration for phase_4 coronary-artery-disease

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2020

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

March 17, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 22, 2021

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

April 17, 2024

Completed
Last Updated

October 8, 2024

Status Verified

October 1, 2024

Enrollment Period

2.5 years

First QC Date

March 17, 2021

Last Update Submit

October 6, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Patient-oriented combined endpoint (clinical endpoint)

    composite of patient-oriented events and significant angina (all-cause death, non fatal myocardial infarction including type 1, 2, 4, unplanned hospitalization for angina or heart failure, unplanned revascularization, SAQ\<90)

    12 months

  • Functional endpoint

    Proportion of patients assigned to medical treatment in the two groups (QFR vs. Reference)

    Upon randomization and following QFR assessment

Secondary Outcomes (5)

  • Seattle angina questionaire summary score

    12 months

  • Seattle angina questionaire summary score

    3 months

  • Unplanned admission

    12 months

  • Patient-oriented composite endpoint

    3 months

  • Patient-oriented composite endpoint

    12 months

Study Arms (2)

Angiography

ACTIVE COMPARATOR

The indication to further coronary intervention will be based on angiographic diameter stenosis.

Diagnostic Test: Assessment of angiographic severity of the stenosis

Quantitative flow ratio (QFR)

EXPERIMENTAL

The indication to further coronary intervention will be based on QFR.

Device: Quantitative flow ratio

Interventions

Quantitative flow ratio (QFR) is a computer method that estimates the hemodynamic relevance of a coronary stenosis based on three-dimensional quantitative coronary angiography (3D QCA)

Quantitative flow ratio (QFR)

The indication to coronary stent intervention will be based on angiography

Angiography

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Successfully treated acute coronary syndrome
  • At least one additional intermediate stenosis (\>30% and \<90%).
  • Patient ≥18 years old

You may not qualify if:

  • Stenoses or patients a priori not amenable to treatment with PCI (at the discretion of two interventional cardiologists - e.g. patients with limited life expectancy, stenosis in very small vessels, very diffuse disease with complex/very calcified stenosis requiring surgery etc).
  • Persistent symptoms or evidence of ischemia requiring intervention of the non-culprit lesion.
  • Any contraindication to PCI according to guidelines
  • An ACS in the period following the index ACS and randomization
  • TIMI (Thrombolysis in Myocardial Infarction) flow grade \< 3 in the culprit vessel
  • Presence of thrombus in the non-culprit lesion
  • Participation in another randomized interventional study interfering with the present protocol
  • Patient unable to give informed consent
  • Women of child-bearing potential or lactating
  • Previous coronary artery bypass surgery CABG
  • Recent (within 30 days) unsuccessful PCI
  • Decompensated congestive heart failure (CHF) or hospitalization due to CHF during the last 3 months
  • Left ventricular ejection fraction \<30%
  • Severe chronic obstructive pulmonary disease (COPD)
  • Severe valvular heart disease
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Center of Cardiology, Cardiology I, university hospital Mainz

Mainz, Rhineland-Palatinate, 55131, Germany

Location

Related Publications (2)

  • Ullrich-Daub H, Olschewski M, Schnorbus B, Belhadj KA, Kohler T, Vosseler M, Munzel T, Gori T. Quantitative flow ratio or angiography for the assessment of non-culprit lesions in acute coronary syndromes, a randomized trial. Clin Res Cardiol. 2025 Jun;114(6):729-737. doi: 10.1007/s00392-024-02484-5. Epub 2024 Jul 9.

  • Ullrich H, Olschewski M, Belhadj KA, Munzel T, Gori T. Quantitative Flow Ratio or Angiography for the Assessment of Non-culprit Lesions in Acute Coronary Syndromes: Protocol of the Randomized Trial QUOMODO. Front Cardiovasc Med. 2022 Apr 4;9:815434. doi: 10.3389/fcvm.2022.815434. eCollection 2022.

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Patients and outcome assessors will be blinded to the randomization group.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Patients will be randomized 1:1 to one of the two study arms. Randomization will be done by using a computer-generated random sequence (Medcalc, Mariakerke, BE).
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

March 17, 2021

First Posted

March 22, 2021

Study Start

October 1, 2020

Primary Completion

April 1, 2023

Study Completion

April 17, 2024

Last Updated

October 8, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will not share

Locations